Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to review the charts of the first 100 patients included in the french compassionate program including patients with Immune Thrombopenia receiving romiplostim.


Clinical Trial Description

Inclusion Criteria:

- Subject has a diagnosis of ITP according to the American Society of Hematology guidelines (George et al., 1996).

- Subject is equal to or greater than 18 years of age.

- Before any study-specific procedure, the appropriate written informed consent must be obtained.

- Subject receiving romiplostim in the compassionate program

- Available follow-up of one-year

Exclusion Criteria:

•Secondary ITP e.g: thrombopenia related to hepatitis C, HIV, Chronic Lymphocytic Leukemia...

The goal of this study is to review retrospectively the charts of the 100 first patients including in this program in France during the period of January 2008 and July 2008. ;


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01013181
Study type Observational
Source Henri Mondor University Hospital
Contact
Status Completed
Phase N/A
Start date January 2008
Completion date August 2009

See also
  Status Clinical Trial Phase
Withdrawn NCT05040776 - COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients Phase 2
Recruiting NCT02906878 - Platelet Kinetics After Platelet Transfusion for the Placement of a Central Venous Catheter N/A
Not yet recruiting NCT06455553 - Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L. N/A
Completed NCT00336687 - Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation. N/A
Not yet recruiting NCT03823079 - Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia Phase 2
Completed NCT04070599 - Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura. Phase 3